Samsung Biologics Co Stock Current Asset
| 207940 Stock | 975,000 25,000 2.50% |
Samsung Biologics Co fundamentals help investors to digest information that contributes to Samsung Biologics' financial success or failures. It also enables traders to predict the movement of Samsung Stock. The fundamental analysis module provides a way to measure Samsung Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Samsung Biologics stock.
Samsung |
Samsung Biologics Co Company Current Asset Analysis
Samsung Biologics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Samsung Biologics Co has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all Republic of Korea stocks is 100.0% higher than that of the company.
Samsung Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Samsung Biologics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Samsung Biologics could also be used in its relative valuation, which is a method of valuing Samsung Biologics by comparing valuation metrics of similar companies.Samsung Biologics is currently under evaluation in current asset category among its peers.
Samsung Fundamentals
| Return On Equity | 0.0751 | |||
| Return On Asset | 0.0422 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 58.92 T | |||
| Shares Outstanding | 71.17 M | |||
| Shares Owned By Insiders | 75.18 % | |||
| Shares Owned By Institutions | 13.80 % | |||
| Price To Book | 6.92 X | |||
| Price To Sales | 23.45 X | |||
| Revenue | 1.57 T | |||
| Gross Profit | 723.35 B | |||
| EBITDA | 737.78 B | |||
| Net Income | 393.59 B | |||
| Total Debt | 1.11 T | |||
| Cash Flow From Operations | 454.6 B | |||
| Earnings Per Share | 2,418 X | |||
| Target Price | 1000000.0 | |||
| Number Of Employees | 10 | |||
| Beta | 0.58 | |||
| Market Capitalization | 57.3 T | |||
| Total Asset | 7.97 T | |||
| Z Score | 30.6 | |||
| Net Asset | 7.97 T |
About Samsung Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Samsung Biologics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Samsung Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Samsung Biologics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Samsung Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Samsung Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Samsung Biologics will appreciate offsetting losses from the drop in the long position's value.Moving together with Samsung Stock
| 0.61 | 302440 | SK Bioscience | PairCorr |
| 0.69 | 326030 | Sk Biopharmaceuticals | PairCorr |
| 0.62 | 298380 | ABL Bio | PairCorr |
| 0.7 | 144510 | Green Cross Lab | PairCorr |
Moving against Samsung Stock
The ability to find closely correlated positions to Samsung Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Samsung Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Samsung Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Samsung Biologics Co to buy it.
The correlation of Samsung Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Samsung Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Samsung Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Samsung Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Samsung Stock
Samsung Biologics financial ratios help investors to determine whether Samsung Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Samsung with respect to the benefits of owning Samsung Biologics security.